Kornimate/medical-research-clean huggingface dataset:
astragalus membranaceus on aneurysmal subarachnoid hemorrhage

Conditions: Aneurysmal Subarachnoid Hemorrhage

Summary: this research is trying to see if am can enhance the clinical prognosis for spontaneous aneurysm ruptured subarachnoid hemorrhage patients.

astragalus membranaceus (am, huang-chi) is a chinese herb used extensively in china as a traditional treatment to treat stroke for a long time, and a number of studies have shown that am can reduce cerebral infarction area and has anti-oxidation activity. our previous studies have demonstrated enhanced recovery of neurologic function in patients with acute hemorrhagic stroke who received am. it is hypothesized that am either reduces inflammatory response or reduces perihematomal edema. subarachnoid hemorrhage secondary to rupture of a cerebral aneurysm is a medical condition associated with a high morbidity and mortality; approximately 10-15% of patients die before reaching medical care, and overall mortality is approximately 45%. of those that survive, 30% suffer permanent disability graded as moderate to severe, and two-thirds of survivors never return to the same quality of life as they had prior to their hemorrhage. a large number of patients (30-70%) who are able to make it to the hospital and have successful treatment of their aneurysm will develop delayed cerebral vasospasm that is related to the blood clot from their initial aneurysm rupture. of patients that survive their initial aneurysm rupture, vasospasm results in an additional 7% mortality and another 7% of severe disabilities secondary to ischemic strokes from severe spasm of cerebral arteries. this research is trying to see if am can enhance the clinical prognosis for spontaneous aneurysm ruptured subarachnoid hemorrhage patients. all procedures done as a part of this study are standard hospital care procedures done to treat aneurysmal subarachnoid hemorrhage according to the aha/asa guideline.

Eligibility criteria:
inclusion criteria: * patients who admitted to the hospital within 24 hours of onset of aneurysmal subarachnoid hemorrhage (sah) stroke * subarachnoid hemorrhage documented on head ct * hunt hess grade 1-4 * both male and female * age more than 20 and less than 80 years older * informed consent obtained from a patient or legal representative before enrollment exclusion criteria: * traumatic or mycotic aneurysms * complication of serious heart or hepatic disease or infection or renal failure * malignant tumor * patients judged to be inappropriate by physician in charge * pregnant / breast feeding women * patients have enrolled or have not yet completed other investigational drug trials within 1 month before screening * ever stroke, and mrs≧3
the efficacy of solifenacin with or without tamsulosin in adult women with overactive bladder (oab)

Conditions: Overactive Bladder

Summary: the aim of the study is to investigate if the combination therapy consisting of anticholinergics plus alpha-blockers could be beneficial for women suffering from overactive bladder (oab).

overactive bladder (oab) describes the symptom complex of urgency, with or without urge incontinence, usually with frequency and nocturia. the lower urinary tract is innervated by both the parasympathetic and the sympathetic nervous system, that act via muscarinic and adrenergic receptors, respectively. antimuscarinics are mainly used for the treatment of patients with oab, especially women. other than antimuscarinics, a1-blockers have been shown in several clinical reports to be useful in treating do caused by neurological diseases.

Eligibility criteria:
inclusion criteria: * female aged 20 ≤ and \< 70 years * history of oab symptoms for ≥ 3 months * international prostate symptom score (ipss) ≥ 8 points at screening and more than 3 in total score and 2 in q 3 index from oabss questionnaire * an average of ≥ 8 micturitions per 24 hours and ≥ 1 urgency (defined as a level of 3 to 5 in a 5 point urinary sensation scale) episode (with or without incontinence) per 24 hours as documented in a 3-day micturition diary exclusion criteria: * uroflowmetry - q max ≤ 10 ml/sec, or post void residual volume ≥ 15% of voided urine * any condition that would contraindicate their usage of anticholinergics or alpha blockers * history of lower urinary tract surgery (e.g. incontinence surgery or electrostimulation) * history of stress urinary incontinence or urinary retention * history of interstitial cystitis, bladder outlet obstruction or other significant genitourinary disorder * pregnant or nursing women * current urinary tract infection * neurological bladder dysfunction * treatment with drugs that may interfere with cyp3a4 metabolic function * significant hepatic or renal disease * any other condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion

Keywords: overactive bladder solifenacin succinate tamsulosin
behavioral signs of consciousness recovery in patients with disorders of consciousness (docsigns)

Conditions: Consciousness Disorder; Brain Injuries

Summary: precise description of behavioral signs denoting transition from unresponsive wakefulness syndrome/vegetative state (uws/vs) to minimally conscious state (mcs) or emergence from mcs after severe brain injury is crucial for prognostic purposes. a few studies have attempted this goal but involved either non-standardized instruments, limited temporal accuracy or samples, or focused on (sub)acute patients. the objective of this study is to describe the behavioral signs that led to a change of diagnosis, as well as the factors influencing this transition, in a large sample of patients with chronic disorders of consciousness after severe brain injury.


Eligibility criteria:
inclusion criteria: * documented medical diagnosis of crs-r-based diagnosis of uws or mcs at admission to the neurorehabilitation program exclusion criteria: * none
specialized radiation therapy in treating patients with stage ii, stage iii, stage iv, or recurrent non-small cell lung cancer and poor performance status

Conditions: Lung Cancer

Summary: rationale: specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. purpose: this phase i trial is studying the side effects and best dose of specialized radiation therapy in treating patients with stage ii, stage iii, stage iv, or recurrent non-small cell lung cancer and poor performance status.

objectives: primary * to escalate the dose of accelerated hypofractionated image-guided conformal radiotherapy to a potent tumoricidal dose without exceeding the maximum-tolerated dose in patients with recurrent or stage ii-iv non-small cell lung cancer and poor performance status. secondary * to evaluate local regional tumor control and overall survival of patients treated with this regimen. outline: patients undergo accelerated hypofractionated image-guided conformal radiotherapy once daily, 5 days a week, for 3 weeks (15 fractions). treatment continues in the absence of disease progression or unacceptable toxicity. after completion of study therapy, patients are followed up periodically for up to 5 years.

Eligibility criteria:
disease characteristics: * histologically or cytologically confirmed non-small cell lung cancer * stage ii-iv and/or recurrent disease * no small cell histology * measurable or evaluable disease * tumor not amenable to surgical resection * tumor not eligible for stereotactic body radiation therapy * no prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields patient characteristics: * zubrod performance status 2-4 * not pregnant or nursing * negative pregnancy test * fertile patients must agree to use effective contraception * must complete all required pretreatment evaluations prior concurrent therapy: * see disease characteristics * more than 1 week since prior chemotherapy or chemoradiation therapy * no concurrent chemotherapy * no other concurrent antineoplastic therapy (including standard-fractionated radiotherapy to the chest, chemotherapy, biological therapy, vaccine therapy, and surgery) 1 week before, during, and for 1 week after completion of study therapy

Keywords: recurrent non-small cell lung cancer stage ii non-small cell lung cancer stage iiia non-small cell lung cancer stage iiib non-small cell lung cancer stage iv non-small cell lung cancer adenocarcinoma of the lung adenosquamous cell lung cancer bronchoalveolar cell lung cancer large cell lung cancer squamous cell lung cancer
motor-cognitive interactive upper limb robot rehabilitation for post-stroke motor dysfunction

Conditions: Stroke

Summary: this study aims to investigate the effects of motor-cognitive interactive robot-assisted training on improving upper limb motor dysfunction after stroke. by observing different combinations of motor and cognitive components in the training, the study will clarify the relationship between the proportion of motor and cognitive elements and the recovery of upper limb motor function. the goal is to optimize the training protocol for upper limb rehabilitation robots and enhance their therapeutic outcomes. participants will be randomly assigned to one of three groups: motor-cognitive interactive robot-assisted training, motor-focused robot-assisted training, or conventional rehabilitation training. training sessions will last 60 minutes, occur 5 times per week, and continue for 4 weeks. researchers will measure changes in upper limb function and monitor for any adverse events during the training.


Eligibility criteria:
inclusion criteria: 1. diagnosis of stroke confirmed by ct or mri. 2. age between 40 and 80 years, with no gender restrictions. 3. first-ever stroke with unilateral limb paralysis. 4. onset of stroke between 2 weeks and 6 months prior, with an fma-ue score of 8-44. 5. willingness to participate and provide written informed consent. exclusion criteria: 1. history of neuromuscular diseases, malignant tumors, or other severe uncontrolled conditions, including cardiac, renal, or hepatic diseases. 2. seated balance score \< 2, or inability to maintain a sitting position for more than 60 minutes. 3. modified ashworth scale score \> 2. 4. visual analog scale (vas) score \> 3 for hemiplegic shoulder pain. 5. boston diagnostic aphasia examination score \< 3. 6. severe visual impairment preventing participation in upper limb robot-assisted rehabilitation training. 7. hamilton depression scale score \>17, indicating moderate to severe depressive symptoms. 8. participation in other clinical trials that may interfere with the results of this study.

Keywords: upeer motor-cognitive interaction robot
behavioral assessment of nociception on ncs-r

Conditions: Disorder of Consciousness; Unresponsive Wakefulness Syndrome; Minimally Conscious State

Summary: the aim of this study was to investigate the relationship between behaviorally assessed consciousness levels and responsiveness to nociception in patients with disorders of consciousness (doc)

patients with a clinical consensus of doc were enrolled. the coma recovery scale-revised (crs-r) was used to assess the doc patients' consciousness levels and the nociception coma scale-revised (ncs-r) was used to evaluate their pain response over one week. furthermore, the relationship between behaviorally assessed consciousness levels and pain response was analyzed.

Eligibility criteria:
inclusion criteria: * (1) at least 18 years old * (2) acquired brain injury * (3) no neuromuscular blockers or sedatives used within 72 hours of enrollment. exclusion criteria: * (1) functional disorders caused by progressive mental diseases * (2) persistent seizures * (3) unstable vital signs * and/or (4) double upper-limb frustration, fracture.

Keywords: disorders of consciousness unresponsive wakefulness syndrome minimally conscious state nociception coma scale-revised
quality of life related to health in spa users

Conditions: Knee Osteoarthritis; Hip Osteoarthritis; Rheumatoid Arthritis

Summary: hypothesis: the spa therapy treatment could improve health-related quality of life (hrqol) in subjects with knee and/or hip osteoarthritis, and patients with rheumatoid arthritis. main objective: analyze if hrqol in patients with knee and/or hip osteoarthritis, and patients with rheumatoid arthritis is modified by spa therapy treatment in the spa of fitero (spain). design: prospective observational study participants: fitero's spa users aged between 45-80 years old, diagnosed with knee and/or hip osteoarthritis, and also with rheumatoid arthritis. at least 40 patients of each type will be included in the study. participants must be receiving a treatment of at least ten days. main variable: the scores obtained in the euroqol5dimensions-5levels questionnaire (eq-5d-5l) (for all subjects), the western ontario macmaster universities osteoarthritis index (womac) questionnaire, for subjects with knee and/or hip osteoarthritis, and the health assessment questionnaire (haq), for subjects with rheumatoid arthritis. other variables: sociodemographic, anthropometric, clinics, and related with spa treatment. follow-up duration: 9 months.


Eligibility criteria:
inclusion criteria: * diagnosed arthrosis of knee or hip and/or rheumatoid arthrosis * balneotherapy treatment of at least 10 days. * physically and mentally able to complete questionnaires exclusion criteria: * have followed a balneotherapy treatment in the six previous month

Keywords: knee osteoarthritis rheumatoid arthritis balneology hip balneology
"impacts of the letter of condolence to the bereaved families experience after a death in icu " - study famirea 22

Conditions: Death; Mourning

Summary: after the death of a patient in the hyper-technical context of intensive care, his relatives are particularly vulnerable and often exhibit symptoms of anxiety, depression, post traumatic stress and complicated grief. the first results of a qualitative study famiréa current (caesar) support the idea that the bereaved relatives suffer from persistent misunderstandings and a feeling of abandonment of the resuscitation team. many families suggest the need for contact with the team after the patient's death. the letter of condolence received by some families allowed them to feel recognized in their pain resuscitation teams. this has led us to ask the question of post-death monitoring and interest to send to bereaved relatives a letter of condolence, as recommended by the american consensus conference in 2004 on good palliative care. this strategy would allow the recognition of both close to the pain but also the strong bond that united the resuscitation team. the hypothesis of the study is that the post-death followed in the form of a letter of condolence sent by the intensive care physician who was in charge of the patient, could reduce the risk of having symptoms of anxiety / depression and post-traumatic stress and reduce the rate of complicated grief. famirea 22 is randomized clinical trial aimin to compare two bereaved groups: one group who did not receive a letter of condolence and a group that received a letter of condolence 15 days after the death.


Eligibility criteria:
inclusion criteria: * death of a relative patient in intensive care whose relatives were interviewed at least once by resuscitation team * death of an adult relative patient * icu stay of the relative patient more than 2 days exclusion criteria: * death of a pregnant woman * opposition to the use of its data by the patient * relative does not speak french * refusal of the relative

Keywords: intensive care unit
prospective registration of severe pneumocystis jiroveci pneumonia requiring icu admission

Conditions: Pneumocystis Jiroveci Pneumonia; Intensive Care Unit

Summary: the investigators aim to set up a multicenter registry study for severe pjp requiring icu admission. the purpose of this study is 1. to establish a prospective severe pjp registry about clinical characteristics, laboratory and radiographic findings, critical care management and outcomes. 2. to explore the predictive factors associated with outcomes ; 3. to compare the difference between pjp patients with hiv and without hiv infection.

pneumocystis jiroveci pneumonia (pjp) is a common opportunistic infection in immunocompromised patients. although the mortality of patients with mild to moderate pjp has declined substantially, the reported outcomes of severe pjp requiring icu admission, especially with mechanical ventilation are grave. the data on this group of patients is very limited and mainly comes from retrospective studies. the investigators aim to set up a multicenter registry study for patient with severe pjp requiring icu admission to provide comprehensive descriptive data on diagnosis, clinical course, critical care management and outcomes in a large cohort. all patients with pjp admitted to the participating icu during a two-year period will be enrolled. the crf will be made available to the participating sites as a printable paper-based crf. the following individual patient data for study participants will be collected: * general demographic information * presence of risk factors for pjp and comorbid condition * use of prophylactic smz/tmp, immunosuppressive medications prior to icu admission * information about pjp and co-infection diagnosis * vital signs, laboratory(blood serum and balf sample) and radiologic data at icu admission and during icu stay * organ failures and severity of the disease at admission, new onset of organ failures during icu stay * medications for pjp, time course and modalities and settings for respiratory support * icu, 28-day mortality, hospital, 90-day mortality

Eligibility criteria:
inclusion criteria: * diagnosis with pjp, confirmed by pcr or methenamine silver stain of sample from balf, aspirate or sputum; * icu admission due to pjp-related respiratory failure exclusion criteria: * no
the caries-arresting effect of incorporating ftcp to naf varnish applied following agno3 in preschool children

Conditions: Early Childhood Caries

Summary: the objective of this study is to compare the effectiveness of 25% agno3 solution plus 5% naf varnish and 25% agno3 solution plus 5% naf varnish with ftcp when applied semi-annually over 30 months in arresting dentine caries of primary teeth among preschool children. half of participants will receive topical application of 25% agno3 solution and 5% naf varnish, while the other half will receive topical application of 25% agno3 solution and 5% naf varnish with ftcp.

aim:the objective of this study is to compare the effectiveness of commercially available of 25% agno3 solution plus 5% naf varnish and 25% agno3 solution plus 5% naf varnish with ftcp when applied semi-annually over 30 months in arresting dentine caries of primary teeth among preschool children. methods: the extension of the consolidated standards of reporting trials 2010 statement will be followed for this 30-month, randomised, double-blinded, equivalence clinical trial. approximately 2,000 kindergarten children will be screened and at least 376 children with caries will be recruited. this sample size is sufficient for an appropriate statistical analysis. the children will be randomly allocated into 2 groups to treat their caries over a 30-month period: group a - biannual application of a 25% agno3 solution followed by a 5% naf varnish, and group b - biannual application of a 25% agno3 solution followed by a 5% naf varnish with functionalized tricalcium phosphate (ftcp).clinical examinations will be conducted at 6-month intervals to assess whether the caries are arrested (primary outcome). confounding factors such as oral hygiene habits will be collected through a parental questionnaire. possible results and implications: as the first of its kind, this study would help to determine whether agno3 followed by 5% naf varnish with and without ftcp are equivalent in arresting dentine caries of primary teeth in preschool children when applied semi-annually.

Eligibility criteria:
inclusion criteria: * have at least one tooth with cavitated dentine carious lesion exclusion criteria: * children have severe forms of dental hypoplasia, under dental treatment or wearing orthodontic devices, have major systemic illness, and are on long-term medication.

Keywords: silver nitrate sodium fluoride dental caries equivalence trial
fasting-mimicking diet in treatment of depressive symptoms in ibd

Conditions: Inflammatory Bowel Diseases; Crohn Disease; Ulcerative Colitis

Summary: inflammatory bowel disease (ibd) is a chronic illness characterized by inflammation of the intestine. many individuals with ibd suffer from depressive symptoms and anxiety which can lead to a decreased quality of life, poor treatment compliance, and higher morbidity and mortality. the object of this clinical trial is to investigate the effects of a fasting mimicking diet in ibd patients who are suffering with symptoms of depression. participants will carry out 3 cycles of a 5-day period of a plant-based low caloric diet or a plant-based caloric sufficient diet following by 3 weeks of eating normally. effects of the dietary intervention on microbes in the gut, immune and metabolic function, and depressive symptoms will be measured. the overall goal is to develop a safe and effective treatment to improve mental health in patients with ibd by targeting the gut microbiome through dietary interventions.

the primary objective of this proof of principle study is to investigate the effects of a fasting mimicking diet on depressive symptoms in patients with inflammatory bowel disease. the specific aims of this project include: 1. determine whether a fasting-mimicking diet is effective in ameliorating depressive symptoms in patients with crohn's disease or ulcerative colitis 2. determine if beneficial effects seen during the interventional period are sustained following cessation of fasting 3. examine effects of the intervention on the gut microbiome and metabolome

Eligibility criteria:
inclusion criteria: * age ≥ 18 and ≤ 65 years at the time of screening * diagnosis of crohn's disease in clinical remission or with mild-moderate disease with harvey bradshaw index (hbi\<8) or diagnosis of ulcerative colitis in clinical remission with partial mayo (pmayo\<7) * suffering from mild-moderate depression with phq-9 ≥5 and ≤ 19 exclusion criteria: * subjects who are reliant on partial or total parenteral nutrition * subjects with prior gastrointestinal surgery and consequences such as short bowel syndrome, ostomy of small or large intestine, total colectomy, proctocolectomy, or ileoanal pouch * subjects with diabetes or celiac disease * subjects with a body mass index (bmi) lower than 18 * subjects suffering from malnutrition or at high risk of malnutrition assessed by a score of ≥6 on the abridged patient generated subjective global assessment (pgsga) * subjects allergic to nuts * subjects currently on a fasting/intermittent type caloric restricted diet * history of psychotic or bipolar disorders or experiencing suicidal thoughts * pregnant women, women who are breast feeding, or women planning on becoming pregnant * subjects with immune-compromised condition other than inflammatory bowel disease (e.g. aids, lymphoma) * subjects with severe uncontrolled cardiovascular or respiratory disease or active malignancy * unable to read english or provide informed consent

Keywords: depression diet microbiome fasting inflammatory bowel disease